<DOC>
	<DOCNO>NCT01557582</DOCNO>
	<brief_summary>The primary endpoint study percent difference VentriPoint Medical System ( VMS ) cMRI estimate end diastolic end systolic right ventricular volume ( RVEDV RVESV ) subject Pulmonary Arterial Hypertension ( PAH ) . The trial define positive mean VMS-cMRI percent difference &lt; 10 % &gt; -10 % 1-sided 0.025 statistical significance level RVEDV RVESV , safety concern VMS procedure .</brief_summary>
	<brief_title>Assessmet Patients With PAH Right Ventricular Volume</brief_title>
	<detailed_description>The objective study : The comparison VMS MRI value EDV , ESV , EF use 75 subject . Secondary objective : The determination VMS inter-observer intra-observer variability quantity use 30 subject .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<criteria>Patients Group 1 Pulmonary Arterial Hypertension IPAH HPAH APAHCTD APAHHIV APAHPoPH APAHDrugs/Toxins APAHCHD repair simple systemic pulmonary shunt , i.e . ASD , VSD and/or PDA APAHCHD unrepaired simple systemic pulmonary shunt , i.e . ASD , VSD and/or PDA Patients expect lie motionless imagine Males females 12 year age old Lack informed consent ( assent appropriate ) Other form PH include inclusion criterion Left heart disease include clinically significant valvular disease , , i.e . moderate great mitral regurgitation stenosis mild great aortic insufficiency stenosis , pericardial disease , LV systolic dysfunction , i.e . LVEF &lt; 40 % LVSF &lt; 22 % , and/or clinically significant LVDD Known/detected arrhythmia interfere image acquisition Implanted cardiac defibrillator , pacemaker , device contain ferromagnetic material Pregnant breastfeeding female Contraindications MRI ( patient undergo MRI ) Clinically significant obstructive restrictive lung disease Subjects know HIV infection clinical laboratory evidence opportunistic pulmonary disease ( e.g. , tuberculosis , Pneumocystis carinii pneumonia , pneumonia ) PAH associate thyroid disorder , glycogen storage disease , Gaucher 's disease , hereditary hemorrhagic telangiectasia , hemoglobinopathy , myeloproliferative disorder splenectomy Any subject congenital heart disease simple congenital systemic shunt specify inclusion criterion PAH associate significant venous capillary involvement ( PCWP ˃ 15 mmHg ) , know pulmonary venoocclusive disease , pulmonary capillary hemangiomatosis Clinically significant cardiac ischemic disease Systemic hypertension define SBP ˃ 160 mmHg and/or DBP ˃ 95 mmHg ( treat untreated ) Moderate severe hepatic impairment , i.e. , ChildPugh Class B C Any subject obstructive sleep apnea require use CPAP BiPAP device</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>IPAH</keyword>
	<keyword>HPAH</keyword>
	<keyword>APAH CTD</keyword>
	<keyword>APAH HIV</keyword>
	<keyword>APAH PoPH</keyword>
	<keyword>APAH Drugs/Toxins</keyword>
	<keyword>APAH CHD repair</keyword>
	<keyword>APAH CHD unrepaired</keyword>
</DOC>